Departing from industry norms, Curie.Bio intentionally allocates a large equity stake to founders. They see this not just as fair but as a utilitarian strategy to gain a competitive advantage in sourcing the rarest and most valuable scientific ideas, which ultimately drives fund returns.

Investors don't look for a specific personality type in biotech founders. Instead, they use pattern recognition to identify a crucial trait: executional excellence. The ability to expertly manage the diverse functions of a biotech company—from clinical to CMC to regulatory—is paramount, and prior experience is the best indicator of this skill.

While product and market are crucial, the most important factor in an early-stage bet is the founder. This is because most startups pivot significantly. A resilient, adaptable founder who can execute through change is more valuable than a perfect initial idea, leading to the ranking: Founder > Market > Product.

For investor Nick Pachuda, a key founder test is whether they can describe "the amazing thing" they are working on in terms of clinical or economic impact. Founders who get bogged down in the technical mechanisms often fail to communicate a compelling vision.

A primary strategy for early-stage investment is partnering with entrepreneurs with a successful track record, often from previous portfolio companies. VCs will back a person they trust, like a former Chief Scientific Officer or a repeat founder, valuing proven execution experience sometimes even more than a nascent scientific concept.

In early-stage investing, the quality of the founder can be more important than the initial business concept. A strong founder is seen as someone who will eventually find success, even if the first idea requires a pivot.

Investors see it as a significant positive signal when a founder can demonstrate a comprehensive understanding of their industry's history, including past failures and adjacent companies. This historical context indicates they have a unique angle of attack and are not simply repeating old mistakes, differentiating them from less-prepared entrepreneurs.

Venture investing is moving beyond pattern-matching for founders from top schools or AI labs. Citing lessons from Vinod Khosla, VC Sandhya Venkatechelam argues that a founder's potential and adaptability are better predictors of success, opening doors for unproven founders who lack a traditional "elite" background.

In the fast-moving AI landscape, investors are concluding that only founder-led companies have the vision and drive to succeed. Any portfolio company, regardless of its revenue, that is not run by its founder is now considered highly likely to fail, making founder retention and motivation paramount.